Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Studies on the Pathogen, Vector Control and Clinical Treatment of Dengue Fever in Guangzhou

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02608047
Recruitment Status : Unknown
Verified November 2015 by Fuchun Zhang, Guangzhou 8th People's Hospital.
Recruitment status was:  Recruiting
First Posted : November 18, 2015
Last Update Posted : November 18, 2015
Sponsor:
Information provided by (Responsible Party):
Fuchun Zhang, Guangzhou 8th People's Hospital

Brief Summary:
The purpose of this study is to elucidate the local epidemic problem and epidemiological characters of dengue fever in Guangzhou, to establish diagnostic and treatment standard and clinical treatment system of severe cases to reduce the morbidity and mortality of dengue fever.

Condition or disease
Dengue Fever

Detailed Description:

To study the epidemiological and pathogenic of dengue virus in Guangzhou, which help to reveal the regular prevalent pattern and the natural epidemic focus of dengue fever. To establish dengue virus sequence database of Guangzhou region, research the biological characteristics and molecular characteristics of dengue fever epidemic strains especially in 2014 in Guangzhou region, to determine the source and variation of this epidemic strains , which finally help to reveal the cause of the pandemic.

To investigate the serum epidemiology of 7800 large groups of people in 12 county-level cities in Guangzhou by stratified random sampling method. It will enrich the research database of the dengue fever serological antibody level survey of people in Guangzhou. After that the investigators could provide a scientific reference for setting up a risk evaluation and implementation of targeted control measures, and also provide reference for analysis of the epidemic situation in other areas.

To study on molecular markers predictive of severe dengue fever and protective immunity after dengue virus infection. The investigators will obtain both serotype-specific and cross-reactive antibodies, which is highly protective neutralizing antibodies. Then the investigators will explore the potential for clinical application about these neutralizing antibodies. The dengue virus were sequenced which caused dengue fever or severe dengue fever in 2014, and do bioinformatics analysis to find the genetic loci which may be responsible for virulence of dengue virus.

To sum up the clinical and laboratory data of dengue fever in 2014, to carry out the research on the diagnosis and treatment of dengue fever, to explore the effectiveness, safety and mechanism of Integrated Chinese and Western medicine treatment for dengue fever patients,to establish of a more perfect system for the diagnosis and treatment of dengue fever in China.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 2000 participants
Observational Model: Case Control
Time Perspective: Retrospective
Official Title: Studies on the Pathogen, Vector Control and Clinical Treatment of Dengue Fever in Guangzhou
Study Start Date : October 2014
Estimated Primary Completion Date : October 2017
Estimated Study Completion Date : October 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dengue Fever

Group/Cohort
dengue patients
Dengue patients confirmed by Non-structural protein and RNA
Healthy controls
Healthy population without any diseases



Primary Outcome Measures :
  1. All cause severe dengue [ Time Frame: One year ]

Biospecimen Retention:   Samples With DNA
Peripheral blood


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Dengue patients
Criteria

Inclusion Criteria:

  • Dengue patients confirmed by dengue virus NS1 or RNA

Exclusion Criteria:

  • Pregnant women
  • Fever diseases caused by other viruses
  • Combined bacterial infection
  • Without complications such as diabetes and tumor.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02608047


Contacts
Layout table for location contacts
Contact: Fuchun Zhang, doctor 8620-83710219 gz8hzfc@126.com

Locations
Layout table for location information
China, Guangdong
Guangzhou NO 8. people's hospital Recruiting
Guangzhou, Guangdong, China, 510060
Contact: Fuchun Zhang    8620-83710219    gz8hzfc@126.com   
Contact: Lingzhai Zhao    8620-83866127    gz8hzlz@126.com   
Sponsors and Collaborators
Guangzhou 8th People's Hospital
Investigators
Layout table for investigator information
Principal Investigator: Fuchun Zhang Guangzhou NO 8. people's hospital

Layout table for additonal information
Responsible Party: Fuchun Zhang, Vice present of hospital, Guangzhou 8th People's Hospital
ClinicalTrials.gov Identifier: NCT02608047     History of Changes
Other Study ID Numbers: 201508020263
First Posted: November 18, 2015    Key Record Dates
Last Update Posted: November 18, 2015
Last Verified: November 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Dengue
Fever
Body Temperature Changes
Signs and Symptoms
Arbovirus Infections
Virus Diseases
Flavivirus Infections
Flaviviridae Infections
RNA Virus Infections
Hemorrhagic Fevers, Viral